References

Anthracycline dose intensification in acute myeloid leukemia

10.1056/nejmoa0904544 · 2009 · External reference

Targeting acute myeloid leukemia through multimodal immunotherapeutic approaches

10.1080/10428194.2021.1992614 · 2022 · External reference

CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia

10.1200/jco.2017.77.6112 · 2018 · External reference

Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy

10.1038/s41392-020-00361-x · 2020 · External reference

Acute myeloid leukemia in the elderly: therapeutic options and choice

10.1080/10428194.2017.1330956 · 2018 · External reference

American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults

10.1182/bloodadvances.2020001920 · 2020 · External reference

More versus less therapy for older adults with acute myeloid leukemia: new perspectives on an old debate

10.1200/edbk_239097 · 2019 · External reference

Azacitidine and venetoclax in previously untreated acute myeloid leukemia

10.1056/nejmoa2012971 · 2020 · External reference

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

10.1182/blood-2018-08-868752 · 2019 · External reference

Long-term follow-up of the phase 3 viale-a clinical trial of venetoclax plus azacitidine for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy

10.1182/blood-2022-158518 · 2022 · External reference

Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A

10.1002/ajh.26692 · 2022 · External reference

How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia

10.1038/s41375-019-0612-8 · 2019 · External reference

Post-remission cytopenia management in patients with AML treated with venetoclax in combination with hypomethylating agents: pre- versus post-VIALE-A real-world experience from a predominantly US community setting

10.1002/cam4.6430 · 2023 · External reference

Reduced venetoclax exposition to seven days of azacitidine is efficient in treatment-naïve patients with acute myeloid leukemia

10.1182/blood-2022-165464 · 2022 · External reference

Venetoclax with hypomethylating agents in newly diagnosed acute myeloid leukemia: a systematic review and meta-analysis of survival data from real-world studies

10.3390/cancers15184618 · 2023 · External reference

Venetoclax resistance: mechanistic insights and future strategies

10.20517/cdr.2021.125 · 2022 · External reference

Outcomes in patients with poor-risk cytogenetics with or without TP53 mutations treated with venetoclax and azacitidine

10.1158/1078-0432.ccr-22-1183 · 2022 · External reference

Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia [published correction appears in Blood. 2023;142(5):494]

10.1182/blood.2022016090 · 2023 · External reference

The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells

10.1158/2159-8290.cd-19-0125 · 2019 · External reference

Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia

10.1182/bloodadvances.2022007083 · 2022 · External reference

Impact of venetoclax and azacitidine in treatment-naïve patients with acute myeloid leukemia and IDH1/2 mutations

10.1158/1078-0432.ccr-21-3467 · 2022 · External reference

Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia

10.1002/ajh.25484 · 2019 · External reference

Reduced duration and dosage of venetoclax is efficient in newly diagnosed patients with acute myeloid leukemia

10.1080/16078454.2023.2293512 · 2024 · External reference

ELN risk stratification is not predictive of outcomes for treatment-naïve patients with acute myeloid leukemia treated with venetoclax and azacitidine

10.1182/blood-2022-169509 · 2022 · External reference

Low-dose weekly decitabine and venetoclax in TP53-mutated myeloid malignancies

10.1200/jco.2022.40.16_suppl.e19005 · 2022 · External reference

RUNX1 mutations correlate with response to venetoclax combination therapies in relapsed/refractory acute myeloid leukemia

10.1016/j.leukres.2021.106735 · 2021 · External reference